Sonnet BioTherapeutics, listed in the US, to acquire Hyperliquid through a merger
Sonnet BioTherapeutics, a biotechnology company listed on Nasdaq, is set to launch Hyperliquid Strategies Inc., a company for accumulating Hyperliquid (HYPE), through a merger. According to The Block on the 14th (local time), Sonnet BioTherapeutics a
2025.7.14